Table 2.
The Comparison Of AEs Between Two Treatment Groups
| AEs | TACE-Apatinib (n=42) | TACE-Alone(n=83) | P-value |
|---|---|---|---|
| Fever | 19(45.2%) | 51(61.4%) | 0.085 |
| Hand-foot syndrome | 20(47.6%) | 0(0%) | <0.001* |
| Fatigue | 12(28.6%) | 21(25.3%) | 0.695 |
| Hypertension | 13(31.0%) | 2(2.4%) | <0.001 |
| Nausea and vomiting | 9(21.4%) | 13(15.7%) | 0.424 |
| Diarrhea | 11(26.2%) | 6(7.2%) | 0.003 |
| Abdominal pain | 8(19.0%) | 19(22.9%) | 0.622 |
| Hoarseness | 4(9.5%) | 0(0%) | 0.012* |
| Epistaxis | 3(7.1%) | 0(0%) | 0.036* |
| Oral or anal ulcer | 8(19.0%) | 0(0%) | <0.001* |
| Proteinuria | 1(2.4%) | 0(0%) | 0.336* |
| Hepatic failure | 0(0%) | 0(0%) | - |
Notes: *Fisher’s exact test. Compared with the TACE-alone group, the incidences of apatinib-related AEs (hand-foot syndrome, hypertension, diarrhea, hoarseness, oral or anal ulcer) were significantly higher in the TACE-apatinib group.
Abbreviations: AEs, adverse events; TACE, transcatheter arterial chemoembolization.